Scientists at the Institute of Innate Immunity work on the most proximal signalling events involved in the pathogenesis of numerous inflammatory diseases.
The discovery of novel targets for pharmacological interference represents an opportunity for translation of our basic research into novel therapies.
In 2017, Eicke Latz co-founded IFM Therapeutics, a spin-out biotech company that has a focus on developing small molecule drugs that target the most proximal initiators of an innate immune response.
In 2020, Eicke Latz co-founded a Stealth Biotech developing novel approaches to treat common metabolic diseases.
In 2020, Eicke Latz, Florian Schmidt and Paul König co-founded DiosCURE SE, a spin-out biotech company that develops next-generation best-in-class immunotherapeutics to prevent and treat SARS-CoV-2.